Business
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\") is proud to be celebrating National Service Dog Month, a time devoted to raising awareness and showing appreciation for the extraordinary work service dogs do every day for the people in their care.\"September is National Service Dog Month. Service dogs are incredible working animals who enable people to live more independently and enjoy a better quality of life. In some cases, service dogs can be the difference between life and death,\" said Lisa Conte, Jaguar's founder, president, and CEO. \"These qualities align with Jaguar's mission of providing supportive care to people and dogs suffering from complex disease states like cancer.\"Conte with her two Jack Russel terriers and her daughter Canalevia®-CA1, Jaguar's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available on Chewy and from veterinarians across the U.S. By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree.\"Our deep commitment to supportive cancer care is a core message of our ongoing \"Make Cancer Less Shitty\" campaign, which seeks to broadly acknowledge the rigors of both short-term and perpetual cancer treatments for metastatic patients. We thankfully now live in the age of targeted therapies for cancer treatment, and thanks to these amazing drugs, cancer patients and metastatic cancer patients are living longer - 5, 10, 20 years longer - frequently rendering cancer a chronic ailment with which to live,\" Conte said. \"The \"Make Cancer Less Shitty\" campaign allows cancer patients to share their voices and stories - their lived experience. We launched the campaign with three remarkable patient ambassadors, and you can find their stories and our commitment on the campaign website: makecancerlessshitty.com. The primary social media channel for the campaign is X, under the handle cancersuckless.\"About the Jagu...